Individualized or Modified Chemotherapy (Dose Adjustment or Delay)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Vir‎: Leuk Res 2011;35(8):991-7.

Indeksirano‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (odpre novo okno)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (odpre novo okno)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Vir‎: Br J Haematol 2014;165(4):497-503.

Indeksirano‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (odpre novo okno)

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. (odpre novo okno)

Dainer PM, Knupp CL, Sartiano GP.

Vir‎: Am J Hematol 1992;40(2):156-7.

Indeksirano‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 (odpre novo okno)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (odpre novo okno)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Vir‎: Lancet Oncol 2013;14(6):525-33.

Indeksirano‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (odpre novo okno)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (odpre novo okno)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Vir‎: N Engl J Med 2020;383(7):617-29.

Indeksirano‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (odpre novo okno)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (odpre novo okno)

El Chaer F, Ballen KK

Vir‎: Br J Haematol 2020;190(5):696-707.

Indeksirano‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (odpre novo okno)

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. (odpre novo okno)

Emadi A, Bade NA, Stevenson B, Singh Z.

Vir‎: Pharmaceuticals (Basel) 2016;9(1):E12.

Indeksirano‎: PubMed 27064021

DOI‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 (odpre novo okno)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (odpre novo okno)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Vir‎: J Clin Oncol 2009;27(28):4733-40.

Indeksirano‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (odpre novo okno)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (odpre novo okno)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Vir‎: Int J Hematol 1997;65(4):415-6.

Indeksirano‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (odpre novo okno)

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. (odpre novo okno)

Garelius H, Grund S, Stockelberg D.

Vir‎: Clin Case Rep 2015;3(5):287-90.

Indeksirano‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 (odpre novo okno)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (odpre novo okno)

Juliusson G.

Vir‎: Am J Hematol 1996;53(1):49.

Indeksirano‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (odpre novo okno)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (odpre novo okno)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Vir‎: Eur J Haematol 2004;72(4):264-7.

Indeksirano‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (odpre novo okno)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (odpre novo okno)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Vir‎: Am J Hematol 1996;51(3):251-2.

Indeksirano‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (odpre novo okno)

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (odpre novo okno)

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

Vir‎: Hematol Oncol 2014;32(1):40-6.

Indeksirano‎: PubMed 23963734

DOI‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 (odpre novo okno)

Cytarabine dose for acute myeloid leukemia. (odpre novo okno)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Vir‎: N Engl J Med 2011;364(11):1027-36.

Indeksirano‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (odpre novo okno)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (odpre novo okno)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Vir‎: Bone Marrow Transplant 2003;32(4):433-6.

Indeksirano‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (odpre novo okno)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (odpre novo okno)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Vir‎: N Engl J Med. 2022;386(16):1519-31.

Indeksirano‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (odpre novo okno)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (odpre novo okno)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Vir‎: Gynecol Oncol 2012;124(2):221-4.

Indeksirano‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (odpre novo okno)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (odpre novo okno)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Vir‎: Leuk Res Rep. 2022 25;18:100355.

Indeksirano‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (odpre novo okno)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (odpre novo okno)

Norfolk DR, Wade P, Carter R.

Vir‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (odpre novo okno)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (odpre novo okno)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Vir‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indeksirano‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (odpre novo okno)

Hematopoietic growth factors: personalization of risks and benefits. (odpre novo okno)

Puhalla S, Bhattacharya S, Davidson NE.

Vir‎: Mol Oncol 2012;6(2):237-41.

Indeksirano‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (odpre novo okno)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (odpre novo okno)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Vir‎: Leuk Lymphoma 2021;62(6):1497-501.

Indeksirano‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (odpre novo okno)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (odpre novo okno)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Vir‎: Blood 2020;135(7):463-71.

Indeksirano‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (odpre novo okno)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (odpre novo okno)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Vir‎: Bone Marrow Transplant 2005;36(8):715-20.

Indeksirano‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (odpre novo okno)

A Mexican way to cope with stem cell grafting. (odpre novo okno)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Vir‎: Hematology 2012;17 Suppl 1:S195-7.

Indeksirano‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (odpre novo okno)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (odpre novo okno)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Vir‎: Blood 2009;113(9):1875-91.

Indeksirano‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (odpre novo okno)

SCT in Jehovah's Witnesses: the bloodless transplant. (odpre novo okno)

Sloan JM, Ballen K.

Vir‎: Bone Marrow Transplant 2008;41(10):837-44.

Indeksirano‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (odpre novo okno)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (odpre novo okno)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Vir‎: Cancer 2006;107(8):1839-43.

Indeksirano‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (odpre novo okno)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (odpre novo okno)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Vir‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

Indeksirano‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (odpre novo okno)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (odpre novo okno)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Vir‎: Onco Targets Ther 2013;7:13-21.

Indeksirano‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (odpre novo okno)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (odpre novo okno)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Vir‎: J Clin Oncol 2007;25(30):4722-9.

Indeksirano‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (odpre novo okno)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (odpre novo okno)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Vir‎: Blood 2020;135(24):2137-45.

Indeksirano‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (odpre novo okno)